Abstract
AbstractTo determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, case series, and case report studies. Fixed-effects analyses demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a ~57% reduction in mortality rate (10%) compared to matched-patients receiving standard treatments (22%; OR: 0.43, P < 0.001). These data provide evidence favouring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
2. The convalescent sera option for containing COVID-19;J. Clin. Invest,2020
3. Joyner, M. J. , et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin. Proc. 95, (2020).
4. Joyner, M. et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. J. Clin. Invest. (2020).
5. Bloch, E. M. , et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. (2020).
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献